Showing 4611-4620 of 7028 results for "".
- Peter Barton Hutt Appointed to Suneva Medical, Inc. Board Of Directorshttps://practicaldermatology.com/news/20141008-peter_barton_hutt_appointed_to_suneva_medical_inc_board_of_directors/2459093/Peter Barton Hutt was appointed a member of the Board of Directors of Suneva Medical, Inc., a privately-held aesthetics company. Mr. Hutt has specialized in food and drug law at the Washington, DC firm of Covington and Burling since 1960, pausing only to serve as Chief Counsel o
- GSK Presents Updated Results from Phase III BREAK-3 Study of Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140929-gsk_presents_updated_results_from_phase_iii_break-3_study_of_tafinlar_dabrafenib/2459102/Results from the planned analysis of the Phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma show benefit for the use of GSK's Tafinlar (dabrafenib) over dacarbazine (DTIC). Forty-five percent of patients treated with dabrafenib only were alive at two
- Provectus ESMO Presentation: Ablative, Bystander Effects Of PV-10https://practicaldermatology.com/news/20140929-provectus_esmo_presentation_ablative_bystander_effects_of_pv-10/2459103/Provectus Biopharmaceuticals, Inc.'s data featured in a presentation during the European Society For Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, show PV-10 has a higher rate of response in injected tumors through its ablative effect, and that the durability of response as well as the
- Medimetriks Pharmaceuticals Announces New Members Elected to Board of Directorshttps://practicaldermatology.com/news/20140923-medimetriks_pharmaceuticals_announces_new_members_elected_to_board_of_directors/2459108/Andrew Lary and William Resnick have been elected as independent directors of the Board of Directors of
- EAU THERMALE AVÈNE AND KLORANE WIN AT 18th ANNUAL ALLURE BEST OF BEAUTY AWARDS 2014https://practicaldermatology.com/news/20140922-eau_thermale_avne_and_klorane_win_at_18th_annual_allure_best_of_beauty_awards_2014/2459109/In the category of Big Breakthrough, whichacknowledged only 16 winners, Avène earned top honors for the Avène XeraCalm A.D Lipid-Replenishing collection, newly launched in January of this year. In its third consecutive year of being recognized in the Best of Beauty Awards,
- Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Boardhttps://practicaldermatology.com/news/20140922-provectus_biopharmaceuticals_appoints_christopher_kaplan_to_its_strategic_advisory_board/2459110/Christopher Kaplan, currently President of Cajetan, LLC, will now be appointed to Provectus Biopharmaceuticals Strategic Advisory Board. Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and
- Syneron's elure™ Wins Allure Magazine's BEST OF BEAUTY Award For The Fourth Consecutive Yearhttps://practicaldermatology.com/news/20140922-synerons_elure_wins_allure_magazines_best_of_beauty_award_for_the_fourth_consecutive_year/2459111/Allure Magazine has named elure™ Advanced Brightening Lotion its “Best Anti-Ager for Discoloration” in its annual Best of Beauty issue, which is published in October every year. This is the fourth consecutive win for elure in Allure Magazine's Best of Beauty issue. elure™ has earned this
- Goldfaden MD Named 2014 CPG Editor's Choice Award Finalist by Informa's SupplySidehttps://practicaldermatology.com/news/20140908-goldfaden_md_named_2014_cpg_editors_choice_award_finalist_by_informas_supplyside/2459126/Informa Exhibitions has named Light Treatment “Dark Spot Corrector” as one of its finalists for the 2014 SupplySide CPG Editor's Choice Awards. Five 2013 consumer packaged goods (CPG) products were selected by the SupplySide editorial team for achievements in innovation and market impact in 20 dif
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conce